Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. They currently have $0.75 price objective on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Other equities analysts have also issued research reports about the stock. ValuEngine lowered shares of Ekso Bionics from a hold rating to a sell rating in a research report on Friday, November 1st. Aegis restated a buy rating and set a $2.90 target price on shares of Ekso Bionics in a research report on Thursday, August 8th. HC Wainwright began coverage on shares of Ekso Bionics in a research report on Monday, October 28th. They set a buy rating and a $1.20 target price for the company. Finally, Cantor Fitzgerald began coverage on shares of Ekso Bionics in a research report on Friday, September 6th. They set an overweight rating and a $1.00 target price for the company. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $1.46.
Shares of NASDAQ EKSO traded down $0.01 during midday trading on Wednesday, hitting $0.60. The stock had a trading volume of 542,300 shares, compared to its average volume of 446,929. The business’s 50 day moving average is $0.57 and its 200-day moving average is $1.09. The company has a quick ratio of 1.69, a current ratio of 2.11 and a debt-to-equity ratio of 0.28. The company has a market cap of $47.22 million, a P/E ratio of -1.36 and a beta of 1.60. Ekso Bionics has a 52 week low of $0.48 and a 52 week high of $2.55.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $3.32 million during the quarter. Ekso Bionics had a negative net margin of 100.36% and a negative return on equity of 376.63%. As a group, analysts expect that Ekso Bionics will post -0.3 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its position in Ekso Bionics by 4,401.9% during the second quarter. Wells Fargo & Company MN now owns 49,521 shares of the company’s stock valued at $63,000 after purchasing an additional 48,421 shares during the last quarter. CVI Holdings LLC bought a new position in Ekso Bionics during the second quarter valued at $494,000. BlackRock Inc. lifted its position in Ekso Bionics by 123.2% during the second quarter. BlackRock Inc. now owns 813,996 shares of the company’s stock valued at $1,035,000 after purchasing an additional 449,348 shares during the last quarter. Wasatch Advisors Inc. bought a new position in Ekso Bionics during the second quarter valued at $2,398,000. Finally, Vanguard Group Inc. lifted its position in Ekso Bionics by 41.2% during the second quarter. Vanguard Group Inc. now owns 2,085,186 shares of the company’s stock valued at $2,648,000 after purchasing an additional 608,759 shares during the last quarter. Institutional investors and hedge funds own 36.44% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.